Brain communications

Dulaglutide's effects on brain function and structure during quitting smoking

Updated

Abstract

After 12 weeks, abstinence rates were 54% for dulaglutide and 68% for placebo.

  • Craving for cigarette smoking significantly decreased across the cohort (P < 0.001).
  • Craving was consistently higher during smoking-cue videos compared to neutral-cue videos (P < 0.001).
  • Participants who achieved smoking abstinence showed significant improvement in working memory (P = 0.02).
  • Small-to-medium reductions in addiction- and reward-related brain activation were observed from baseline to week 12.
  • No significant differences were found between dulaglutide and placebo in clinical, functional, or structural outcomes.

Simplified

Key numbers

15 of 28
Abstinence Rate
Abstinence rate in dulaglutide group was 54% and placebo group was 68%.
QSU-G estimated mean difference −9.10
Craving Reduction
Craving scores halved following the 12-week intervention.
40.49
Working Memory Improvement
Faster reaction time in those who achieved abstinence compared to those who continued smoking.

Full Text

What this is

  • Dulaglutide, a GLP-1 receptor agonist, was tested for its effects on smoking cessation alongside standard treatments.
  • The study involved 71 participants randomized to receive either dulaglutide or placebo for 12 weeks.
  • Outcomes included abstinence rates, craving reduction, working memory performance, and neuroimaging assessments.

Essence

  • Dulaglutide did not provide additional benefits over placebo in smoking cessation outcomes when combined with standard care. While craving for cigarettes decreased, no significant differences were observed in abstinence rates or cognitive performance.

Key takeaways

  • Abstinence rates were 54% for dulaglutide and 68% for placebo, with no significant difference (P = 0.27). Both groups experienced a notable reduction in craving for smoking after 12 weeks.
  • Working memory performance improved significantly among participants who achieved smoking abstinence, but no differences were found between dulaglutide and placebo groups.
  • Neuroimaging showed small-to-medium reductions in activation of addiction-related brain regions, but these changes did not differ significantly between the treatment groups.

Caveats

  • The study's reliance on concurrent varenicline treatment may have masked any potential benefits of dulaglutide. Additionally, the sample's characteristics may limit the generalizability of the findings.
  • Dulaglutide's dosing and duration may not have been sufficient to observe significant effects, particularly in a predominantly normal-weight sample.

Simplified

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free